Repositorio Institucional
Repositorio Institucional
CONICET Digital
  • Inicio
  • EXPLORAR
    • AUTORES
    • DISCIPLINAS
    • COMUNIDADES
  • Estadísticas
  • Novedades
    • Noticias
    • Boletines
  • Ayuda
    • General
    • Datos de investigación
  • Acerca de
    • CONICET Digital
    • Equipo
    • Red Federal
  • Contacto
JavaScript is disabled for your browser. Some features of this site may not work without it.
  • INFORMACIÓN GENERAL
  • RESUMEN
  • ESTADISTICAS
 
Artículo

Crystal violet structural analogues identified by in silico drug repositioning present anti-Trypanosoma cruzi activity through inhibition of proline transporter TcAAAP069

Martínez Sayé, Melisa SoledadIcon ; Gauna, Lucrecia Antonella; Valera Vera, Edward AugustoIcon ; Reigada, ChantalIcon ; Miranda, Mariana ReneéIcon ; Pereira, Claudio AlejandroIcon
Fecha de publicación: 01/2020
Editorial: Public Library of Science
Revista: Neglected Tropical Diseases
ISSN: 1935-2735
Idioma: Inglés
Tipo de recurso: Artículo publicado
Clasificación temática:
Bioquímica y Biología Molecular

Resumen

Background: Crystal violet (CV) was used for several years in blood banks to eliminate the parasite Trypanosoma cruzi in endemic areas in order to prevent transfusiontransmitted Chagas disease. One mechanism of action described for CV involves inhibition of proline uptake. In T. cruzi , proline is essential for host cell infection and intracellular differentiation among other processes, and can be obtained through the proline permease TcAAAP069.Methodology/Principal Findings: CV inhibited proline transporter TcAAAP069 andparasites overexpressing this permease were 47-fold more sensitive to this compound than control parasites. Using CV as reference molecule, loratadine, cyproheptadine,olanzapine and clofazimine were identified as structurally related compounds to CV (structural analogues) by in silico drug repurposing through a similarity-based virtual screening protocol. All these already-approved drugs for clinical use inhibited TcAAAP069 activity with different efficacies and also presented trypanocidal action in epimastigotes, trypomastigotes and amastigotes of the Y, CL Brener and DM28c T.cruzi strains. Finally, a synergistic effect between benznidazole and the CV chemical analogues was evidenced by combination and dose-reduction indexes values in epimastigotes and trypomastigotes of the Y strain.Conclusions/Significance: Loratadine, cyproheptadine and clofazimine inhibitTcAAAP069 proline transporter and also present trypanocidal effect against all T. cruzi life stages in strains from three different DTUs. These CV structural analogues could be a starting point to design therapeutic alternatives to treat Chagas disease by finding new indications for old drugs. This approach, called drug repurposing is a recommended strategy by the World Health Organization to treat neglected diseases, like Chagas disease, and combination therapy may improve the possibility of success of repositioned drugs.
Palabras clave: TRYPANOSOMA CRUZI , CHAGAS DISEASE , PROLINE TRANSPORT , DRUG REPURPOSING , TRANSPORT INHIBITORS
Ver el registro completo
 
Archivos asociados
Thumbnail
 
Tamaño: 1.781Mb
Formato: PDF
.
Descargar
Licencia
info:eu-repo/semantics/openAccess Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution 2.5 Unported (CC BY 2.5)
Identificadores
URI: http://hdl.handle.net/11336/104955
URL: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0007481
DOI: https://doi.org/10.1371/journal.pntd.0007481
Colecciones
Articulos(IDIM)
Articulos de INST.DE INVEST.MEDICAS
Citación
Martínez Sayé, Melisa Soledad; Gauna, Lucrecia Antonella; Valera Vera, Edward Augusto; Reigada, Chantal; Miranda, Mariana Reneé; et al.; Crystal violet structural analogues identified by in silico drug repositioning present anti-Trypanosoma cruzi activity through inhibition of proline transporter TcAAAP069; Public Library of Science; Neglected Tropical Diseases; 14; 1; 1-2020; 1-23; e0007481
Compartir
Altmétricas
 

Enviar por e-mail
Separar cada destinatario (hasta 5) con punto y coma.
  • Facebook
  • X Conicet Digital
  • Instagram
  • YouTube
  • Sound Cloud
  • LinkedIn

Los contenidos del CONICET están licenciados bajo Creative Commons Reconocimiento 2.5 Argentina License

https://www.conicet.gov.ar/ - CONICET

Inicio

Explorar

  • Autores
  • Disciplinas
  • Comunidades

Estadísticas

Novedades

  • Noticias
  • Boletines

Ayuda

Acerca de

  • CONICET Digital
  • Equipo
  • Red Federal

Contacto

Godoy Cruz 2290 (C1425FQB) CABA – República Argentina – Tel: +5411 4899-5400 repositorio@conicet.gov.ar
TÉRMINOS Y CONDICIONES